Loncastuximab tesirine for treating relapsed or refractory diffuselargeB-celllymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments Loncastuximab tesirine for treating relapsed or refractory diffuselargeB-celllymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments Technology appraisal guidance Published: 31 January 2024 www.nice.org.uk/guidance/ta947 /terms-and-conditions#notice-of-rights).Page 3 of211 Recommendations 1.1 Loncastuximab tesirine is recommended as an option for treating relapsed or refractory diffuselargeB-celllymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after 2 or more systemic treatments in adults, only if: • they have previously had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated
Axicabtagene ciloleucel (diffuselargeB-celllymphoma, second line) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Axicabtagen-Ciloleucel (DLBCL und HGBL, Zweitlinie) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (Association of the Scientific Medical Societies) CD cluster of differentiation CR complete response CTCAE Common Terminology Criteria for Adverse Events DLBCL diffuselargeB-celllymphoma ECOG PS Eastern Cooperative Oncology Group Performance Status EFS event-free survival EMA European Medicines Agency EORTC QLQ-C30 European Organisation
Lisocabtagene Maraleucel (Breyanzi) - For the treatment of adult patients with diffuselargeB-celllymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising f View of Lisocabtagene Maraleucel (Breyanzi) | Canadian Journal of Health Technologies Return to Article DetailsLisocabtagene Maraleucel
Glofitamab for relapsed or refractory diffuselargeB-celllymphoma after two or more lines of systemic therapy Published: 17 February 2025 Driving Better Decision-Making in Healthcare Page 1 Glofitamab for relapsed or refractory diffuselargeB-celllymphoma after two or more lines of systemic therapy Technology Guidance from the MOH Drug Advisory Committee Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuselargeB-celllymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price
Tafasitamab with lenalidomide added to R-CHOP for previously untreated diffuselargeB-celllymphoma 25 FEBRUARY 2025 Tafasitamab with lenalidomide added to R-CHOP for previously untreated diffuselargeB-celllymphoma Tafasitamab with lenalidomide, added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), is currently in clinical development for the treatment ofpreviously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuselargeB-celllymphoma (DLBCL). DLBCL is a type of blood cancer that develops when whiteblood cells, called lymphocytes, grow out of control. The affected lymphocytes lose their infection-fighting ability making the body more susceptible to infection. The first symptom ofDLBCL is often a painful swelling in the neck
Epcoritamab bysp (Epkinly) - To treat relapsed or refractory diffuselargeB-celllymphoma and high-grade B-cell lymphoma Skip to main contentSkip to FDA SearchSkip to footer links An official website of the United States government Here's how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search Home Drugs Drug Approvals and Databases Drugs@FDADrug Approval Package
Glofitamab gxbm (Columvi) - To treat diffuselargeB-celllymphoma Skip to main contentSkip to FDA SearchSkip to footer links An official website of the United States government Here's how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search Home Drugs Drug Approvals and Databases Drugs@FDADrug Approval Package: COLUMVIShareTweetLinkedinEmailPrintCompany: Genentech
Odronextamab (Ordspono) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuselargeB?celllymphoma (r/r DLBCL) Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuselargeB‑celllymphoma (r/r DLBCL) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * Year AIHTA - Publications - Search - Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuselargeB‑celllymphoma (r/r DLBCL) Rothschedl, E. and Grössmann, N.(2024):Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed
Summary of COHERE Finland's recommendation on loncastuximab tesirine in the treatment of diffuselargeb-celllymphoma or high-grade b-cell lymphoma SUMMARY 1(2) 19 December 2023 STM023:00/2023 VN/16744/2023 Council for Choices in Health Care in Finland Meritullinkatu 8, Helsinki PO Box 33, FI-00023 GOVERNMENT, FINLAND Tel. +358 295 16001 www.palveluvalikoima.fi email : palveluvalikoima.stm@gov.fi SUMMARY OF COHERE FINLAND’S RECOMMENDATION ON LONCASTUXIMAB TESIR-INE IN THE TREATMENT OF DIFFUSELARGEB-CELLLYMPHOMA OR HIGH-GRADE B-CELL LYMPHOMA At its meeting of 19 December 2023, the Council for Choices in Health Care in Finland (CO-HERE Finland) adopted a recommendation on loncastuximab tesirine in the treatment of dif-fuse large B-cell lymphoma or high-grade B-cell lymphoma
Polatuzumab Vedotin (Polivy) - large B-cell lymphoma (LBCL), including diffuselargeB-celllymphoma (DLBCL) View of Polatuzumab Vedotin (Polivy) | Canadian Journal of Health TechnologiesReturn to Article DetailsPolatuzumab Vedotin (Polivy)